|[June 17, 2014]
ZS Pharma, Inc. Announces Pricing of Initial Public Offering
COPPELL, Texas --(Business Wire)--
ZS Pharma, Inc., a biopharmaceutical company developing novel treatments
for kidney, cardiovascular, liver and metabolic disorders, today
announced the pricing of its initial public offering of 5,944,444 shares
of its common stock at a price to the public of $18.00 per share. The
shares are expected to begin trading on The NASDAQ Global Market on June
18, 2014 under the symbol "ZSPH". In addition, ZS Pharma has granted the
underwriters a 30-day option to purchase up to an additional 891,667
shares of common stock at the initial public offering price, less
underwriting discounts and commissions. The offering is expected to
close on or about June 23, 2014, subject to customary closing conditions.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are
acting as joint book-running managers for the offering. BMO Capital
Markets Corp. is acting as lead manager and William Blair & Company,
L.L.C. is acting as co-manager.
A registration statement relating to these securities has been filed
with, and was declared effective on June 17, 2014 by, the U.S.
Securities and Exchange Commission.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, the securities described above, nor
shall there be any sale of the securitis in any state or jurisdiction
in which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
This offering will be made only by means of a prospectus. A final
prospectus for the offering, when available, may be obtained from:
J.P. Morgan Securities LLC
c/o Broadridge Financial Solutions
Long Island Avenue
Edgewood, NY 11717
Telephone: (866) 803-0204
Credit Suisse Securities (USA) LLC
Attention: Prospectus Department
New York, NY 10010
Telephone: (800) 221-1037
You may also obtain a copy of the final prospectus free of charge by
visiting the Securities and Exchange Commission's website at http://www.sec.gov
under the registrant's name, "ZS Pharma, Inc."
This press release contains forward-looking statements within the
meaning of the federal securities laws. These forward-looking statements
involve certain risks and uncertainties, including, among others, our
business plans may change as circumstances warrant and securities of ZS
Pharma, Inc. may not ultimately be offered to the public because of
general market conditions or other factors.
About ZS Pharma
ZS Pharma is a specialty pharmaceutical company based in Coppell, Texas.
ZS Pharma's lead therapeutic candidate, ZS-9, is an investigational
treatment for hyperkalemia that is being evaluated in late-stage
clinical trials to demonstrate its ability to safely and effectively
remove excess potassium from the blood and maintain normal potassium
levels. ZS Pharma is also pursuing the discovery of additional drug
candidates that utilize its novel selective ion-trap technology for the
treatment of kidney and liver diseases. Additional information is
available at www.zspharma.com.
[ Back To TMCnet.com's Homepage ]